Bayer Applies For Domestic Application Of Regorafenib For GIST
This article was originally published in PharmAsia News
Executive Summary
Bayer Pharmaceuticals, which is applying for the approval of regorafenib for the treatment of colorectal cancer, announced Dec. 21 it also applied for the drug’s application for unresectable or metastatic gastrointestinal stromal tumors (GIST).